The Canadian Cancer Trials Group (CCTG) has launched a Phase 2 study of CFI-400945 in combination with Imfinzi (durvalumab) for the treatment of advanced or metastatic triple negative breast cancer (TNBC). CFI-400945 is an investigational compound that stops cell division by inhibiting a protein called polo-like kinase 4. Because unchecked cell division is a hallmark of cancer cells, blocking it may kill these cells or slow their growth. Imfinzi, developed by AstraZeneca, is a type of immunotherapy called an…
You must be logged in to read/download the full post.
The post Phase 2 Trial of Combination Treatment for Advanced Breast Cancer Launched appeared first on BioNewsFeeds.